Hiroaki Nagamine   Masakazu Yashiro   Naoki Yoshimoto   Motohiro Izumi   Akira Sugimoto   Kenji Nakahama   Koichi Ogawa   Yoshiya Matsumoto   Kenji Sawa   Yoko Tani   Hiroyasu Kaneda   Shigeki Mitsuoka   Kazuhiro Yamada   Tetsuya Watanabe   Kazuhisa Aasai   Kazuhiro Fukumura   Akila Mayeda   Tomoya Kawaguchi   
Anticancer research 43(10) 4663-4672 2023年10月 [査読有り]
BACKGROUND/AIM: Immune checkpoint inhibitors (ICIs) are currently a standard treatment tool for non-small cell lung cancer (NSCLC). RNA-binding motif protein 17 (RBM17), a splicing factor, is frequently over-expressed in NSCLC, but little is known...